Genmab A/S (GMAB) Announces Submissions of Regulatory Applications for Epcoritamab for Relapsed/Refractory LBCL and DLBCL

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. IBM
10. HOOD

Go back to Genmab A/S (GMAB) Announces Submissions of Regulatory Applications for Epcoritamab for Relapsed/Refractory LBCL and DLBCL

Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DL

October 28, 2022 8:45 AM EDT

Media Release

COPENHAGEN, Denmark; October 28, 2022

Genmab has Submitted Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) for epcoritamabEuropean Medicines Agency (EMA) has validated Marketing Authorization Application (MAA) for epcoritamab submitted by AbbVieThe submissions are supported by the EPCORE NHL-1 open-label, multi-center phase 2 trial evaluating the safety and preliminary efficacy of epcoritamab in adult... More